云南沃森生物技术股份有限公司 关于子公司向银行申请授信额度的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 云南沃森生物技术股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第五届董事会第三十二次会议和第五届监事会第二十三次会议，审议通过 了《关于子公司向银行申请授信额度的议案》。公司子公司玉溪沃森生物技术有 限公司（以下简称"玉溪沃森"）、玉溪泽润生物技术有限公司（以下简称"玉 溪泽润"）根据业务发展及日常运营需要，拟向渤海银行股份有限公司昆明分行 （以下简称"渤海银行"）、交通银行股份有限公司玉溪分行（以下简称"交通 银行"）申请授信额度，详细情况如下： 一、申请银行授信额度的基本情况 为保障子公司业务发展及日常运营资金需求，扩宽公司融资渠道，降低资金 成本，玉溪沃森和玉溪泽润拟向上述银行申请授信额度，授信可用于子公司研发、 生产、销售及日常经营支出。拟申请授信额度情况详见下表： | 序号 | 授信银行 | 授信主体 | 拟申请 授信金额 | 授信期限 | 授信品种 | 授信用途 | | --- | --- | --- | -- ...

关于 2025 年第三季度计提资产减值准备及核销资产的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 证券代码：300142 证券简称：沃森生物 公告编号：2025-061 云南沃森生物技术股份有限公司 云南沃森生物技术股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第五届董事会第三十二次会议和第五届监事会第二十三次会议，审议通过 了《关于 2025 年第三季度计提资产减值准备及核销资产的议案》。根据《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所创业板上市公司自律监管指 南第 1 号——业务办理》《企业会计准则》等相关规定的要求，公司及下属子公 司对 2025 年第三季度末各类存货、应收账款、其他应收款、应收退货成本、固 定资产、在建工程、长期股权投资、无形资产、金融资产等资产进行了全面清查， 对各类存货的可变现净值，应收款项回收的可能性，固定资产、在建工程、金融 资产及无形资产等的可变现性进行了充分的评估和分析，认为上述资产中部分资 产存在一定的减 ...

证券代码：300142 证券简称：沃森生物 公告编号：2025-059 云南沃森生物技术股份有限公司 第五届监事会第二十三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 云南沃森生物技术股份有限公司（以下简称"公司"）第五届监事会第二十 三次会议于 2025 年 10 月 27 日在公司会议室召开，会议通知于 10 月 22 日以电 子邮件方式发出。本次会议以现场会议结合通讯表决的方式召开，应参加会议监 事 3 人，实际参加会议监事 3 人。会议由监事会主席丁世青女士主持。本次会议 的召集、召开符合《公司法》等法律法规、部门规章、规范性文件及《公司章程》 的规定。 二、监事会会议审议情况 1、审议通过了《关于<2025 年第三季度报告>的议案》 监事会对公司 2025 年第三季度报告审核后，发表如下审核意见：董事会编 制和审议公司 2025 年第三季度报告的程序符合法律、行政法规和中国证监会的 规定；公司 2025 年第三季度报告的内容和格式符合中国证监会和深圳证券交易 所的规定；报告内容真实、准确、完整地反映了公司报告 ...

证券代码：300142 证券简称：沃森生物 公告编号：2025-058 云南沃森生物技术股份有限公司 第五届董事会第三十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 本议案获得通过。 公司《2025 年第三季度报告》已经公司董事会审计委员会审议通过。具体 内容详见证监会指定的创业板信息披露网站巨潮资讯网。 2、审议通过了《关于 2025 年第三季度计提资产减值准备及核销资产的议案》 董事会同意公司根据《企业会计准则》《深圳证券交易所创业板股票上市规 则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》和《深圳证券交易所创业板上市公司自律监管指南第 1 号——业务办理》等 相关法规及公司会计政策的规定，2025 年第三季度计提资产减值准备及核销资 产事项。 云南沃森生物技术股份有限公司（以下简称"公司"）第五届董事会第三十 二次会议于 2025 年 10 月 27 日在公司会议室召开，会议通知于 10 月 22 日以电 子邮件方式发出。本次会议以现场会议结合通讯表决的方式召开，应参加会议董 ...

2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 云南沃森生物技术股份有限公司 2025 年第三季度报告 证券代码：300142 证券简称：沃森生物 公告编号：2025-060 云南沃森生物技术股份有限公司 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）声明：保证季 度报告中财务信息的真实、准确、完整。 3.第三季度财务会计报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比 | | --- | --- | --- | --- | --- | | | | 增减 | | 上年同期增减 | | 营业收入（元） | 564,595,546.37 | -20.25% | 1,718,807,933.37 | ...

Policy Developments - The 11th batch of national drug centralized procurement opened for bidding on October 27, involving 55 varieties across fields such as anti-infection and anti-tumor drugs. The procurement rules have been optimized to ensure clinical stability, quality assurance, and to prevent price collusion [1] Drug and Device Approvals - China Medical's subsidiary, Keyi Pharmaceutical, received a drug registration certificate for Fusidic Acid Cream, which is used for skin infections caused by Staphylococcus and Streptococcus. The drug has a projected domestic sales of approximately 500 million yuan in 2023 and 524 million yuan in 2024 [2] - Watson Bio's mRNA vaccine for respiratory syncytial virus has received clinical trial approval from the National Medical Products Administration. This vaccine is developed to prevent lower respiratory tract diseases caused by the virus, with no similar products approved in China yet [3] Financial Reports - Heng Rui Medicine reported a 25% year-on-year increase in net profit for the first three quarters of 2025, with total revenue of 23.188 billion yuan, a 14.85% increase [4] - Yiling Pharmaceutical reported a significant 80.33% year-on-year increase in net profit for the first three quarters of 2025, despite a 7.82% decline in total revenue [5] Capital Market Activities - Novartis signed a strategic cooperation agreement with Kangzhe Pharmaceutical for the exclusive import and commercial promotion of two ophthalmic drugs in China, effective from November 1, 2025. This agreement aligns with Novartis's strategy to focus on four core therapeutic areas [6][7] Industry Developments - The first biomanufacturing industry fund in Shanghai has been established, aiming to integrate resources from enterprises, universities, and research institutions to promote technological breakthroughs and business growth [9] Regulatory Issues - The Hunan Provincial Commission for Discipline Inspection reported on 15 cases of local officials interfering in hospital engineering and drug procurement, highlighting ongoing issues of corruption and misconduct in the healthcare sector [10]

Group 1 - Watson Bio has received approval from the National Medical Products Administration for a clinical trial of its respiratory syncytial virus mRNA vaccine, developed in collaboration with Fudan University and other partners [1] - The approval allows for clinical trials aimed at preventing lower respiratory tract diseases caused by respiratory syncytial virus, with a validity period of three years for the trial implementation [1] - As of the first half of 2025, Watson Bio's revenue composition shows that self-developed vaccines account for 94.82%, intermediate product revenue for 4.67%, and other business segments for 0.50% [1] Group 2 - The company has a market capitalization of 18.1 billion yuan [1]

证券日报网讯10月27日晚间，沃森生物（300142）发布公告称，公司、复旦大学、上海蓝鹊生物医药有 限公司及公司子公司玉溪沃森生物技术有限公司、北京沃森创新生物技术有限公司联合研发并共同申请 临床试验的呼吸道合胞病毒mRNA疫苗，于近日获得国家药品监督管理局签发的《药物临床试验批准通 知书》。 ...

Core Insights - Watson Bio has received approval from the National Medical Products Administration for a clinical trial of its mRNA vaccine targeting respiratory syncytial virus (RSV) [1][2] Group 1: Clinical Trial Approval - The clinical trial approval notification for the RSV mRNA vaccine was issued with the registration numbers 2025LP02790 and 2025LP02791 [1] - The vaccine is classified as a preventive biological product and aims to prevent lower respiratory tract diseases caused by RSV infection [1] Group 2: Vaccine Development - The vaccine is developed through a collaboration between Watson Bio, Fudan University, and Blue Magpie Biopharmaceuticals, utilizing a self-established mRNA vaccine technology platform [2] - The vaccine design is based on a highly conserved sequence of the RSV-A strain F protein, incorporating various mutations for optimized antigen expression [2]

Core Insights - Yunnan Watson Bio-Technology Co., Ltd. has signed an agreement with Pharmaniaga Berhad's subsidiary for the distribution and local production of the 13-valent pneumococcal conjugate vaccine (PCV-13) in Malaysia [1][2] - The collaboration aims to enhance the local production and commercialization of PCV-13, which is crucial for preventing invasive diseases caused by pneumococcus, particularly in children under six years old [1] - The annual demand for PCV vaccines in Malaysia is approximately 1.5 million doses, with around 500,000 newborns each year, indicating a stable market demand [1] Company and Industry Summary - The partnership marks a significant achievement in Watson Bio's strategy to expand its "Chinese medicine" overseas, being the sixth localization project for PCV-13 after similar initiatives in Morocco, Indonesia, Egypt, Mexico, and Bangladesh [2] - The collaboration was facilitated by Revon Bio FZ-LLC through its resource network, highlighting the role of international partnerships in expanding vaccine accessibility [2]